- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02766985
Rasch-analysis of Clinical Severity in FSHD (ROC-FSHD)
April 11, 2018 updated by: University of Kansas Medical Center
The purpose of this study is to make a standardized and scalable Rasch-built clinical severity scale to help in finding genetic and environmental modifiers of disease in Facioscapulohumeral muscular dystrophy (FSHD).
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
44
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- University of Utah
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Particpants with genetically verified FSHD types 1 and 2.
Description
Inclusion Criteria:
- Genetic confirmation of FSHD (either FSHD-1 or FSHD-2)
Exclusion Criteria:
- Do not understand English
- Unable to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
FSHD
Participants with FSHD-1 or FSHD-2.
No intervention is given to participants.
Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FSHD Clinical Severity Scale
Time Frame: 1 day
|
Measure severity of FSHD.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brooks scale
Time Frame: 1 day
|
Measures upper extremity function.Scores on the scale range from 1-6.
A score of 1 means the person can elevate their arms above their head while arms remain straight.
6 means the person cannot elevate their arms to their mouth and do not have useful function of their hands.
|
1 day
|
Vignos scale
Time Frame: 1 day
|
Measures lower extremity function.
Scores on the scale range from 1-10.
A score of 1 means the person can walk and climb stairs without assistance.
A score of 10 means the person is bedridden.
|
1 day
|
Iowa Oral Performance Instrument (IOPI)
Time Frame: 1 day
|
IOPI measures lip and tongue strength by measuring the amount of pressure a person can exert on the tool.
|
1 day
|
Manual muscle testing
Time Frame: 1 day
|
Measure person's range of motion.
Scored on a scale with range of 0-5.
Score of 0 means no movement.
Score of 5 means the person has a full range of movement.
|
1 day
|
Quantitative strength testing
Time Frame: 1 day
|
1 day
|
|
Functional testing
Time Frame: 1 day
|
1 day
|
|
Reparatory function testing
Time Frame: 1 day
|
1 day
|
|
Patient-reported outcome
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
April 18, 2017
Study Completion (Actual)
April 18, 2017
Study Registration Dates
First Submitted
March 22, 2016
First Submitted That Met QC Criteria
May 6, 2016
First Posted (Estimate)
May 10, 2016
Study Record Updates
Last Update Posted (Actual)
April 12, 2018
Last Update Submitted That Met QC Criteria
April 11, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00003640
- UL1TR000001 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facioscapulohumeral Muscular Dystrophy
-
Avidity Biosciences, Inc.RecruitingPhase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)Muscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy Type 1 | Fascioscapulohumeral Muscular Dystrophy... and other conditionsUnited States, United Kingdom, Canada
-
Centre Hospitalier Universitaire de NiceRecruitingType 1 Facioscapulohumeral Muscular DystrophyFrance
-
aTyr Pharma, Inc.CompletedFacioscapulohumeral Muscular Dystrophy (FSHD)United States, Netherlands, France, Italy
-
Grete Andersen, MDCompletedFSHD - Facioscapulohumeral Muscular DystrophyDenmark
-
aTyr Pharma, Inc.CompletedFacioscapulohumeral Muscular Dystrophy (FSHD)United States, France, Italy
-
Fulcrum TherapeuticsActive, not recruitingFacioscapulohumeral Muscular Dystrophy 1Netherlands
-
Ning Wang, MD., PhD.Recruiting
-
Centre Hospitalier Universitaire de NiceRecruitingFacioscapulohumeral Muscular Dystrophy 1France, Canada
-
Hoffmann-La RocheActive, not recruitingFacioscapulohumeral Muscular Dystrophy (FSHD)United States, United Kingdom, Italy, Denmark
-
Fulcrum TherapeuticsActive, not recruitingFacioscapulohumeral Muscular Dystrophy (FSHD)United States, Spain, Italy, Denmark, Canada, Germany, France, Netherlands, United Kingdom